CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Tonic Motor Activation (TOMAC) for Restless Legs Syndrome — Coverage Criteria

Policy governing coverage determinations for bilateral peroneal nerve stimulation (TOMAC) to treat primary restless legs syndrome (RLS) refractory to medication for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyTonic Motor Activation (TOMAC) for Restless Legs Syndrome — Coverage Criteria

Policy CodePolicy N/A

Change TypeAdministrative update — no material clinical changes

Effective DateJun 1, 2026

Next Review DateFeb 18, 2026

Key ActionVerify member benefits and eligibility before providing services.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance

De NovoRegulatory status

2 codesCodes not covered

RCTs+metaEvidence

Coverage Determination and Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage determination for TOMAC as a treatment for RLS

Covered when ALL of the following are met:

Overall coverage stance: Tonic Motor Activation (TOMAC) is not covered for Medicare Advantage plans and is not medically necessary for Commercial products because the evidence is insufficient to determine improvement in net health outcome.

Policy states TOMAC is indicated clinically only for moderate-to-severe primary RLS refractory to pharmacologic treatment, but coverage is denied based on evidence assessment.

Clinical indication: Patient has moderate-to-severe primary restless legs syndrome (RLS) that is refractory to pharmacologic treatment.

TOMAC is not a first-line therapy; it is intended for cases refractory to standard treatments such as iron supplementation, gabapentinoids, and behavioral measures.

Therapy sequencing: Conventional first-line therapies (eg, iron supplementation, gabapentinoids, lifestyle modifications) have been attempted and were ineffective, not tolerated, or contraindicated.

Clinical pathway describes TOMAC as indicated only after failure of pharmacologic treatment.

For Commercial products, TOMAC for medication-refractory restless legs syndrome is considered not medically necessary because the evidence is insufficient to demonstrate improvement in net health outcome. The available literature includes randomized controlled trials, nonrandomized studies, and a systematic review/meta-analysis that showed some symptom and sleep quality benefits versus sham but were limited by small sample sizes, short follow-up, potential unblinding, and lack of long-term randomized data; these limitations prevent concluding durable clinical benefit.

Provider Responsibilities and Billing Actions

Note

Prior Authorization

Prior authorization is not applicable for this policy.

Step Therapy

Therapy Sequencing

TOMAC (transcutaneous osseous magnetic stimulation) is not a first-line therapy. It is indicated only for moderate-to-severe primary restless legs syndrome (RLS) that is refractory to pharmacologic therapy; first-line options include iron supplementation, gabapentinoids, and lifestyle modifications.

Documentation Required

Verify Benefits and Eligibility

Verify benefits and eligibility prior to providing services. Coverage may vary by contract; refer to the member's Evidence of Coverage / Subscriber Agreement or contact the provider call center for member-specific information.

Denial Risk

Billing Denial Risk for Listed Codes

Billing denial risk: the following codes will be considered not covered / not medically necessary for this indication and may be denied if billed for external lower extremity nerve stimulation for RLS.

A4544 — Electrode for external lower extremity nerve stimulator for restless legs syndrome
E0743 — External lower extremity nerve stimulator for restless legs syndrome, each

Clinical Background

Restless legs syndrome (RLS) is a neurologic disorder characterized by an uncontrollable urge to move the legs, often accompanied by uncomfortable sensations and associated sleep disturbance. Patients commonly experience periodic limb movements during sleep, and standard management emphasizes pharmacologic therapies (for example, alpha-2-delta ligands or dopaminergic agents), iron repletion when indicated, and behavioral measures prior to consideration of device-based interventions such as TOMAC.

Key Definitions

inv-10: TOMAC — Tonic Motor Activation definition and key points

DefinitionTonic Motor Activation (TOMAC): bilateral peroneal nerve stimulation using electrodes on the lower legs to deliver high-frequency stimulation to the common peroneal nerves, producing sustained low‑level tibialis anterior muscle contractions.

Mechanism of actionStimulation activates the tibialis anterior muscle to mimic voluntary leg movements and sends afferent feedback to the central nervous system, potentially suppressing abnormal sensory signals that drive the urge to move.

Clinical intentDesigned to reproduce movement-like activation (eg, walking/stretching) that can relieve RLS symptoms by modulating spinal and supraspinal pathways.

Device targetingTargets the common peroneal nerves located near the fibula in the lower legs for tonic motor activation (distinct from sensory-focused TENS).

Distinguishing featuresDiffers from TENS by targeting motor pathways with sustained, high-frequency bilateral stimulation aimed at tonic activation rather than pulsed sensory pain relief.

inv-11: PLMD — Periodic limb movement disorder definition

DefinitionPeriodic limb movement disorder (PLMD): periodic limb movements during sleep that occur without restless legs syndrome (RLS) or related disorders.

Relation to RLSPLMS (periodic limb movements during sleep) commonly co-occur with RLS, but when PLMS occurs in the absence of RLS or other related disorders it is classified as PLMD.

Clinical impactPLMD can contribute to sleep disturbance and impaired daytime functioning similar to RLS-associated periodic limb movements.